Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
May 16, 2022 07:30 ET
|
Galera Therapeutics
Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of...
Galera Announces Plan to Submit Avasopasem NDA by Year End
May 16, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
May 02, 2022 07:00 ET
|
Galera Therapeutics
Incidence of Grade 3 esophagitis substantially reduced in patients treated with avasopasem compared to literature No Grade 4 or 5 esophagitis in patients treated with avasopasem MALVERN, Pa, May...
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:00 ET
|
Galera Therapeutics
MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
March 10, 2022 07:00 ET
|
Galera Therapeutics
Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission Data readouts from AESOP in...
Galera to Present at H.C. Wainwright BioConnect Conference
January 06, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
December 14, 2021 07:00 ET
|
Galera Therapeutics
Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045)Topline results...
Galera to Present at Two Upcoming Investor Conferences in November
November 15, 2021 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
November 10, 2021 07:00 ET
|
Galera Therapeutics
Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in...
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis
October 19, 2021 07:00 ET
|
Galera Therapeutics
Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met Trial demonstrated relative reduction in all key SOM endpoints, including more than halving the median...